Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03300583
Other study ID # 16.0151
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2018
Est. completion date December 30, 2020

Study information

Verified date February 2021
Source Kingston University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to choose healthier options and also transform the relationship between service user and caregivers from one in which the former is a passive recipient of care to one in which they are an active partner in decision-making. Interstitial lung disease (ILD) is one such long term condition. Patients with ILD often express concern about the lack of information on possible rehabilitation programmes and other services that could potentially improve self-management of the disease. In addition, there is a general perception about a lack of co-ordination between health care professionals especially in relation to referral to services for comprehensive management of the disease. Therefore, the needs of patients with ILD and their carers, and possible gaps in service provision need to be explored further. In this study, the investigators propose to explore the needs of ILD patients from all types of ILD and all stages of severity and to also involve carers and clinicians. The investigators will conduct three focus groups for patients and carers and six one-to-one interviews with clinicians to explore perceptions about service gaps and needs in two ILD centres in South and North London, UK. This study will provide valuable information to develop the building blocks of a self-management resource and will enable the investigators to make it specific to the different types of ILD.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date December 30, 2020
Est. primary completion date October 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility PATIENTS Inclusion Criteria: - Diagnosed with Interstitial Lung disease (all types apart from sarcoidosis) - Age >18 years - At least one consultation with a health care professional Exclusion Criteria: - Diagnosed with sarcoidosis - Unable to communicate in English - Severity of condition and commodities preventing participation CAREGIVERS Inclusion Criteria: - Currently caring for a participant with ILD Exclusion Criteria: - Unable to communicate in English CLINICIANS: Inclusion Criteria: - Involved in the clinical management and treatment of ILD patients Exclusion Criteria: - Health care professionals not directly involved in management or treatment of ILD patients

Study Design


Intervention

Behavioral:
Focus groups
Focus group discussion led by the PI and facilitated by another researcher.
Semi-structured interviews
1:1 semi-structured interviews led by the PI

Locations

Country Name City State
United Kingdom St George's Hospital London London
United Kingdom University College Hospital London

Sponsors (3)

Lead Sponsor Collaborator
Kingston University St. George's Hospital, London, University College London Hospitals

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perceptions of service needs and gaps in current services among ILD patients, carers and clinicians Exploratory method, conducted using semi-structured 1:1 interviews and focus groups 1-2 hours
Secondary Differences in perceptions between participating ILD patients, carers and clinicians Exploratory method, conducted using semi-structured interviews and focus groups 1-2 hours
Secondary Presentation and explanation of diagnosis and its implications to ILD patients and carers Exploratory method using semi-structured interviews and focus groups 1-2 hours
Secondary Presentation and explanation of information about the management of the disease to ILD patients and carers Exploratory method using semi-structured interviews and focus groups 1-2 hours
Secondary Recommended solutions for better self-management Exploratory method using semi-structured interviews and focus groups 1-2 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3
Completed NCT00532233 - SD, IL-13 Production Rate in IPF Phase 2
Completed NCT00540475 - Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry